Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

ClinicalTrials.gov ID: NCT01565668

Public ClinicalTrials.gov record NCT01565668. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects With FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Study identification

NCT ID: NCT01565668
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Daiichi Sankyo; Industry
Enrollment: 76 participants

Conditions and interventions

Conditions

Leukemia, Myeloid, Acute

Interventions

AC220 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2012
Primary completion: Feb 28, 2015
Completion: Feb 28, 2015
Last update posted: Dec 26, 2019

2012 – 2015

United States locations

U.S. sites: 18
U.S. states: 12
U.S. cities: 15

Facility	City	State	ZIP	Site status
UCLA School of Medicine	Los Angeles	California	90095	—
Northwestern University	Chicago	Illinois	60611	—
University of Chicago	Chicago	Illinois	60637	—
University of Maryland Greenebaum Cancer Center	Baltimore	Maryland	21201	—
John Hopkins University	Baltimore	Maryland	21231	—
Tufts University School of Medicine-Tufts Medical Center	Boston	Massachusetts	02111	—
University of Minnesota	Minneapolis	Minnesota	55455	—
Mayo Clinic	Rochester	Minnesota	55905	—
Hackensack University Medical Center	Hackensack	New Jersey	07601	—
Memorial Sloan-Kettering Cancer Center	New York	New York	10021	—
Weill Cornell Medical College	New York	New York	10065	—
Penn State Milton S. Hershey Medical Center	Hershey	Pennsylvania	17033	—
Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
Medical University of South Carolina, Hollings Cancer Center	Charleston	South Carolina	29403	—
Vanderbilt University, Vanderbilt Ingram Cancer Center	Nashville	Tennessee	37232	—
UT Southwestern Medical Center, Simmons Cancer Center	Dallas	Texas	75390	—
MD Anderson	Houston	Texas	77030	—
Fred Hutchinson Cancer Research Center	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01565668, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 26, 2019 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01565668 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →